119 related articles for article (PubMed ID: 30899428)
21. Correction: Sirt3-mediated mitophagy protects tumor cells against apoptosis under hypoxia.
Qiao A; Wang K; Yuan Y; Guan Y; Ren X; Li L; Chen X; Li F; Chen AF; Zhou J; Yang JM; Cheng Y
Oncotarget; 2018 Jun; 9(43):27318. PubMed ID: 29930768
[TBL] [Abstract][Full Text] [Related]
22. Correction: Metabolic pathway for the universal fluorescent recognition of tumor cells.
Fernandez-Carrascal A; Garcia-Algar M; Nazarenus M; Torres-Nuñez A; Guerrini L; Feliu N; Parak WJ; Garcia-Rico E; Alvarez-Puebla RA
Oncotarget; 2019 Nov; 10(61):6643. PubMed ID: 31762944
[TBL] [Abstract][Full Text] [Related]
23. Correction: MiR-451 as a new tumor marker for gastric cancer.
Shen Y; Gong JM; Zhou LL; Sheng JH
Oncotarget; 2019 Oct; 10(59):6396. PubMed ID: 31695848
[TBL] [Abstract][Full Text] [Related]
24. Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.
Hu Z; Hu Y; Liu X; Xi R; Zhang A; Liu D; Xie Q; Chen L
Oncotarget; 2018 Oct; 9(81):35283. PubMed ID: 30443295
[TBL] [Abstract][Full Text] [Related]
25. Correction: Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1.
Yin SY; Efferth T; Jian FY; Chen YH; Liu CI; Wang AHJ; Chen YR; Hsiao PW; Yang NS
Oncotarget; 2018 Aug; 9(63):32271. PubMed ID: 30181816
[TBL] [Abstract][Full Text] [Related]
26. Correction: Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting.
Kim JY; Han JH; Park G; Seo YW; Yun CW; Lee BC; Bae J; Moon AR; Kim TH
Oncotarget; 2018 Jun; 9(42):26977. PubMed ID: 29928495
[TBL] [Abstract][Full Text] [Related]
27. Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H
Oncotarget; 2018 Mar; 9(24):17255. PubMed ID: 29683149
[TBL] [Abstract][Full Text] [Related]
28. Correction: Molecular response prediction in CML: novel ideas?
Wolf D; Sopper S
Oncotarget; 2018 Nov; 9(88):35871. PubMed ID: 30533202
[TBL] [Abstract][Full Text] [Related]
29. Correction: Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis.
Marciel MP; Khadka VS; Deng Y; Kilicaslan P; Pham A; Bertino P; Lee K; Chen S; Glibetic N; Hoffmann FW; Matter ML; Hoffmann PR
Oncotarget; 2018 Jul; 9(56):30937. PubMed ID: 30112120
[TBL] [Abstract][Full Text] [Related]
30. Correction: Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis.
Fu S; Wen X; Han F; Long Y; Xu G
Oncotarget; 2018 Jan; 9(5):6658. PubMed ID: 29465717
[TBL] [Abstract][Full Text] [Related]
31. Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience.
Yuan Y; Yost SE; Yim J; Yuan YC; Solomon NM; Mambetsariev I; Pal S; Frankel P; Salgia R; Neuhausen SL; Mortimer J
Oncotarget; 2017 Sep; 8(37):62817. PubMed ID: 28977992
[TBL] [Abstract][Full Text] [Related]
32. Correction: Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Wang LT; Chiou SS; Chai CY; Hsi E; Wang SN; Huang SK; Hsu SH
Oncotarget; 2018 Dec; 9(102):37807. PubMed ID: 30701034
[TBL] [Abstract][Full Text] [Related]
33. Correction: Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer.
Terlizzi M; Colarusso C; De Rosa I; De Rosa N; Somma P; Curcio C; Sanduzzi A; Micheli P; Molino A; Saccomanno A; Salvi R; Aquino RP; Pinto A; Sorrentino R
Oncotarget; 2018 Jun; 9(50):29537. PubMed ID: 30034638
[TBL] [Abstract][Full Text] [Related]
34. Correction:
Mellai M; Cattaneo M; Storaci AM; Annovazzi L; Cassoni P; Melcarne A; De Blasio P; Schiffer D; Biunno I
Oncotarget; 2018 Aug; 9(66):32731. PubMed ID: 30220979
[TBL] [Abstract][Full Text] [Related]
35. Correction: The optimal time of initiation of renal replacement therapy in acute kidney injury: A meta-analysis.
Luo K; Fu S; Fang W; Xu G
Oncotarget; 2018 Jan; 9(5):6657. PubMed ID: 29465716
[TBL] [Abstract][Full Text] [Related]
36. Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
Novohradsky V; Zajac J; Vrana O; Kasparkova J; Brabec V
Oncotarget; 2018 Oct; 9(85):35599. PubMed ID: 30473754
[TBL] [Abstract][Full Text] [Related]
37. Correction: Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells.
Tsai CH; Tsai HC; Huang HN; Hung CH; Hsu CJ; Fong YC; Hsu HC; Huang YL; Tang CH
Oncotarget; 2018 Oct; 9(85):35598. PubMed ID: 30473753
[TBL] [Abstract][Full Text] [Related]
38. Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.
Reeves PM; Abbaslou MA; Kools FRW; Vutipongsatorn K; Tong X; Gavegnano C; Schinazi RF; Poznansky MC
Oncotarget; 2018 Jul; 9(54):30472. PubMed ID: 30101001
[TBL] [Abstract][Full Text] [Related]
39. Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Khatri A; Gu JJ; McKernan CM; Xu X; Pendergast AM
Oncotarget; 2019 Oct; 10(57):6045-6046. PubMed ID: 31666936
[TBL] [Abstract][Full Text] [Related]
40. Correction: P-cadherin mutations are associated with high basal Wnt activity and stemness in canine mammary tumor cell lines.
Timmermans-Sprang E; Collin RWJ; Henkes A; Philipsen M; Mol JA
Oncotarget; 2020 Feb; 11(5):573. PubMed ID: 32082491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
